{"id":26649,"date":"2020-12-09T08:00:00","date_gmt":"2020-12-09T08:00:00","guid":{"rendered":"http:\/\/ca228bca7cb39165b5816915321afc6d"},"modified":"2024-11-03T15:15:52","modified_gmt":"2024-11-03T15:15:52","slug":"front-line-anti-pd1-treatment-outperforms-braf-mek-therapy-in-brafv600-mutant-advanced-melanoma","status":"publish","type":"post","link":"https:\/\/ogkologos.com\/en\/front-line-anti-pd1-treatment-outperforms-braf-mek-therapy-in-brafv600-mutant-advanced-melanoma\/","title":{"rendered":"Front-line Anti-PD1 Treatment Outperforms BRAF\/MEK Therapy in BRAFV600-mutant Advanced Melanoma"},"content":{"rendered":"<p>Findings from a propensity-matched survival analysis presented at the <a href=\"https:\/\/www.esmo.org\/meetings\/past-meetings\/esmo-immuno-oncology-virtual-congress-2020\" class>ESMO Immuno-Oncology Virtual Congress 2020<\/a>, held from 9 to 12 December 2020, suggest that patients with advanced melanoma and a <em>BRAF<sup>V600<\/sup><\/em> mutation derive an enhanced survival benefit from first-line treatment with anti-PD-1 monotherapy, as compared to BRAF\/MEK inhibitors.<\/p>\n<p>Jesper van Breeschoten of the Scientific Department, Dutch Institute for Clinical Auditing in Leiden, Netherlands and department of medical oncology Amsterdam UMC, Netherlands,&nbsp;&nbsp;explained that currently the data are inconclusive on whether to use anti-PD-1 monotherapy or BRAF\/MEK inhibitors as first-line treatment in patients with advanced <em>BRAF<sup>V600<\/sup><\/em>-mutant melanoma, prompting this propensity score matching study, which compared the two types of agents in this patient population.&nbsp;&nbsp;<\/p>\n<p>The investigators identified patients diagnosed with unresectable stage III or IV melanoma who had a known <em>BRAF<sup>V600<\/sup><\/em>-mutation and were registered in the Dutch Melanoma Treatment Registry. From 2014 to 2017, a total of 254 of these patients received first-line treatment with anti-PD-1 monotherapy and 330 received first-line treatment with BRAF\/MEK inhibitors. Of these, 310 patients were matched based on their propensity scores using the nearest neighbour and the optimal matching method for inclusion in the matched cohort.<\/p>\n<h4>Overall survival favoured immune checkpoint inhibitor as first-line therapy for patients with <em>BRAF<sup>V600<\/sup><\/em>-mutant advanced melanoma<\/h4>\n<p>Comparison of these two first-line treatment strategies in the matched cohort showed that patients receiving anti-PD-1 antibodies demonstrated a higher median and 12-month overall survival (OS) compared to patients treated with first-line BRAF\/MEK inhibitors.&nbsp;&nbsp;<\/p>\n<p>Median OS was 42.3 months (95% confidence interval [CI] 37.3-not estimable) with anti-PD-1 monotherapy compared to 19.8 months (95% CI 16.7-24.3) with BRAF\/MEK inhibition in the matched cohort. The 24\u2013month OS rates were 64.00% (95% CI 58.2-70.4) compared to 41.7% (95% CI 34.2-51.0), with the respective treatments.<\/p>\n<p>Full results are accepted for publication in the <em>British Journal of Cancer<\/em>.<\/p>\n<h4>Conclusions<\/h4>\n<p>The authors concluded that these data suggest that anti-PD-1 monotherapy is the preferred first-line treatment in matched patients with <em>BRAF<sup>V600<\/sup><\/em>-mutant advanced melanoma and relatively favourable patient and tumour characteristics.<\/p>\n<p>They await results from currently ongoing randomised clinical studies to confirm this finding.<\/p>\n<p>No external funding was disclosed for this analysis.<\/p>\n<h4>Reference<\/h4>\n<p>37P \u2013 Breeschoten JV, Wouters M, Hilarius D, <em>et al.<\/em> First-line BRAF\/MEK-inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: A propensity-matched survival analysis. <a href=\"https:\/\/www.esmo.org\/meetings\/past-meetings\/esmo-immuno-oncology-virtual-congress-2020\" class>ESMO Immuno-Oncology Virtual Congress 2020<\/a> (9-12 December).<\/p>\n<p><a href=\"http:\/\/www.esmo.org\/oncology-news\/front-line-anti-pd1-treatment-outperforms-braf-mek-therapy-in-brafv600-mutant-advanced-melanoma\">Source<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Findings from a propensity-matched survival analysis presented at the ESMO Immuno-Oncology Virtual Congress 2020, held from 9 to 12 December 2020, suggest that patients with advanced melanoma and a BRAFV600 mutation derive an enhanced survival benefit from first-line treatment with anti-PD-1 monotherapy, as compared to BRAF\/MEK inhibitors. Jesper van Breeschoten of the Scientific Department, Dutch [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"footnotes":""},"categories":[5137],"tags":[],"class_list":["post-26649","post","type-post","status-publish","format-standard","hentry","category-world-news"],"_links":{"self":[{"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/posts\/26649","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/comments?post=26649"}],"version-history":[{"count":1,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/posts\/26649\/revisions"}],"predecessor-version":[{"id":45479,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/posts\/26649\/revisions\/45479"}],"wp:attachment":[{"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/media?parent=26649"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/categories?post=26649"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/tags?post=26649"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}